Franciscan Physician Network
Welcome,         Profile    Billing    Logout  
 4 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stankovic, Goran
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Completed
4
339
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
01/24
06/24
NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated
N/A
28
Europe, RoW
Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention
Ceric Sàrl, Abbott
Out of Hospital Cardiac Arrest
01/23
01/23
FULL REVASC, NCT02862119: Ffr-gUidance for compLete Non-cuLprit REVASCularization

Completed
N/A
1542
Europe
FFR Treatment Arm, Conservative Treatment Arm
Felix Bohm, Uppsala University, The Swedish Research Council, Swedish Heart Lung Foundation, Abbott, Boston Scientific Corporation
Coronary Artery Disease, ST-elevation Myocardial Infarction
07/23
07/23
SINERGY-ACUTE, NCT04506047: Acute and Long-term Outcomes of Patients With Acute Myocardial Infarction Treated With PCI

Recruiting
N/A
30000
RoW
Percutaneous Coronary Intervention
Clinical Centre of Serbia, Institute of Cardiovascular Diseases Vojvodina, Clinical Hopital Center Zemun, University Hospital Medical Center Bezanijska Kosa, Clinical Centre of Kragujevac, Clinical Hospital Center Zvezdara
Acute Myocardial Infarction, Coronary Artery Disease
01/24
01/25
NCT05905835: Treatment of PAF With the Synaptic System

Recruiting
N/A
185
US
Synaptic Cryoablation System
Synaptic Medical Corporation
Paroxysmal Atrial Fibrillation
07/24
12/24
AIM HIGHer, NCT05064709: Assessment of CCM in HF With Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/26
02/26
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
RADIATE-VT, NCT05765175: Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia

Recruiting
N/A
380
US
Varian Cardiac Radioablation (CRA), Catheter Ablation (CA)
Varian, a Siemens Healthineers Company
Tachycardia, Ventricular
05/26
05/30
Czer, Lawrence
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Chugh, Atul
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
Canfield, Angela
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Brittsan, Angela
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stankovic, Goran
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Completed
4
339
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
01/24
06/24
NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated
N/A
28
Europe, RoW
Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention
Ceric Sàrl, Abbott
Out of Hospital Cardiac Arrest
01/23
01/23
FULL REVASC, NCT02862119: Ffr-gUidance for compLete Non-cuLprit REVASCularization

Completed
N/A
1542
Europe
FFR Treatment Arm, Conservative Treatment Arm
Felix Bohm, Uppsala University, The Swedish Research Council, Swedish Heart Lung Foundation, Abbott, Boston Scientific Corporation
Coronary Artery Disease, ST-elevation Myocardial Infarction
07/23
07/23
SINERGY-ACUTE, NCT04506047: Acute and Long-term Outcomes of Patients With Acute Myocardial Infarction Treated With PCI

Recruiting
N/A
30000
RoW
Percutaneous Coronary Intervention
Clinical Centre of Serbia, Institute of Cardiovascular Diseases Vojvodina, Clinical Hopital Center Zemun, University Hospital Medical Center Bezanijska Kosa, Clinical Centre of Kragujevac, Clinical Hospital Center Zvezdara
Acute Myocardial Infarction, Coronary Artery Disease
01/24
01/25
NCT05905835: Treatment of PAF With the Synaptic System

Recruiting
N/A
185
US
Synaptic Cryoablation System
Synaptic Medical Corporation
Paroxysmal Atrial Fibrillation
07/24
12/24
AIM HIGHer, NCT05064709: Assessment of CCM in HF With Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/26
02/26
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
RADIATE-VT, NCT05765175: Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia

Recruiting
N/A
380
US
Varian Cardiac Radioablation (CRA), Catheter Ablation (CA)
Varian, a Siemens Healthineers Company
Tachycardia, Ventricular
05/26
05/30
Czer, Lawrence
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Chugh, Atul
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
Canfield, Angela
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Brittsan, Angela
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26

Download Options